Preoperative serum levels of follicle stimulating hormone (FSH) and prognosis in invasive breast cancer

European Journal of Surgical Oncology

Volumn 30, Issue 5, 2004, Pages 495-500

  Eskelinen, M ^a   Norden T ^b   Lindgren, A ^c   Wide, L ^d   Adami, H O ^e,f   Holmberg, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Kullbergska Hospital   (Sweden)

^c FALUN HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f HARVARD CENTER FOR CANCER PREVENTION   (United States)

Author keywords

Breast cancer; Follicle stimulating hormone; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; FOLLITROPIN; METHOTREXATE; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLIMACTERIUM; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MEDICAL RESEARCH; MULTIVARIATE ANALYSIS; PARTIAL MASTECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RADIOIMMUNOASSAY; TUMOR VOLUME;

EID: 2542531429     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2004.01.018     Document Type: Article

References (24)

1. Wang DY, Goodwin PR, Bulbrook RD, Hayward JL. Plasma FSH and LH in post-menopausal women with breast cancer. Eur J Cancer 1976;12:305-311.
2. Adami H-O, Rimsten Å, Wide L. Pineal gland FSH and Breast-cancer aetiology. Lancet 1978;16:1312-1313.
3. Bird CE, Cook S, Owen S, Sterns EE, Clark AF. Plasma concentrations of C-19 steroids, estrogens, FSH, LH and protactin in postmenopausal women with and without breast cancer. Oncology 1981;38:365-368.
4. Dowsett M, Macaulay V, Gledhill J et al. Control of aromatase in breast cancer cells and its importance for tumor growth. J Steroid Biochem Mol Biol 1993;44:605-609.
5. Hsu C-J, Hammond JM. Gonadotropins and estradiol stimulate immunoreactive insulin-like growth factor-I production by porcine granulosa cells in vitro. Endocrinology 1987;120: 198-207.
6. Hsueh AJ, Bicsak TA, Jia X-C et al. Granulosa cells as hormone targets: the role of biologically active follicle-stimulating hormone in reproduction. Rec Progress Horm Res 1989;45:209-277.
7. Fujinaga H, Yamoto M, Nakano R, Shima K. Epidermal growth factor binding sites in porcine granulosa cells and their regulation by follicle-stimulating hormone. Biol Reprod 1992;46:705-709.
8. Stewart AJ, Westley BR, May FEB. Modulation of the proliferation response of breast cancer cells to growth factors by oestrogen. Br J Cancer 1992;66:640-648.
9. Dickson RB, Johnson MD, Bano M et al. Growth factors in breast cancer: mitogenesis to transformation. J Steroid Biochem Mol Biol 1992;43:69-78.
10. Valverius EM, Ciardiello F, Heldin N-H et al. Stromal influences on transformation of human mammary epihelial cells overexpressing c-myc and SV40T. J Cell Physiol 1990; 145:207-216.
11. Bar RS, Boes M, Dake BL, Booth BA, Henley SA, Sandra A. Insulin, insulin-like growth factors, and vascular endothelium. Am J Med 1988;85:59-70.
12. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res 1995; 30:825-834.
13. Penn LJZ, Brooks MW, Laufer EM, Land H. Negative autoregulation of c-myc transcription. EMBO J 1990;9: 1113-1121.
14. Rustgi AK, Dyson N, Bernards R. Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product. Nature 1991;352:541-544.
15. Hankinson SE, Willett WC, Colditz GA et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396.
16. Liljegren G, Holmberg L, Adami H-O, Westman G, Graffman S, Bergh J. Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. J Natl Cancer Inst 1994;86:717-722.
17. Wide L, Nillius SJ, Gemzell C, Roos P. Radioimmunosorbent assay of follicle-stimulating hormone and lutenizing hormone in serum and urine from men and women. Acta Endocrinol (Copenh) 1973;174(Suppl.):1-58.
18. Cox DR. Regression models and life tables with discussion. J R Stat Soc 1972;34:187-194.
19. Nyström L, Larsson L-G, Rutqvist LE et al. Determination of cause of death among breast cancer cases in the Swedish randomized mammography screening trials. A comparison between official statistics and validation by an endpoint committee. Acta Oncol 1995;34:145-152.
20. Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986;315:559-563.
21. Pujol P, Daures J-P, Thezenas S, Guilleux F, Rouanet P, Grenier J. Changing estrogen and progesterone reeceptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 1998;83:698-705.
22. Hatt JE, Schoenfeld A, Martin KA, Crowley WF. Hypothalamic gonadotropin-releasing hormone secretion and and follicle-stimulating hormone dynamics during the luteal-follicular transition. J Clin Endocrinol Metab 1992;74:600-607.
23. Schipper I, de Jong FH, Fauser BJCM. Lack of correlation between maximum early follicular phase serum follicle stimulating hormone concentrations and menstrual cycle characteristics in women under the age of 35 years. Human Reprod 1998;13:1442-1448.
24. Pujol P, Daures J-P, Brouillet J-P, Chang S, Rouanet P, Bringer J, Grenier J, Maudelonde T. A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma. Cancer 2001;91: 1854-1861.